|
Originally published In Press as doi:10.1074/jbc.M110712200 on March 27, 2002
J. Biol. Chem., Vol. 277, Issue 23, 20927-20933, June 7, 2002
Dose-dependent Activation of Antiapoptotic
and Proapoptotic Pathways by Ethanol Treatment in Human Vascular
Endothelial Cells
DIFFERENTIAL INVOLVEMENT OF ADENOSINE*
Jie
Liu,
Zhigang
Tian ,
Bin
Gao, and
George
Kunos§
From the Laboratory of Physiologic Studies, National Institute on
Alcohol Abuse and Alcoholism, Bethesda, Maryland 20892
Received for publication, November 7, 2001, and in revised form, March 20, 2002
 |
ABSTRACT |
Moderate but not heavy drinking has been
found to have a protective effect against cardiovascular morbidity. We
investigated the effects of ethanol (EtOH) treatment on the cell
survival-promoting phosphatidylinositol 3-kinase (PI3K)/Akt pathway in
cultured human umbilical vein endothelial cells (HUVEC). Exposure of
cells to 2-20 mM EtOH resulted in rapid (<10 min)
induction of Akt phosphorylation that could be prevented by pertussis
toxin or the PI3K inhibitors wortmannin and LY294002. Among the
downstream effectors of PI3K/Akt, p70S6 kinase, glycogen synthase
kinase 3 / , and I B- were phosphorylated, the latter
resulting in 3-fold activation of NF- B. EtOH also activated p44/42
mitogen-activated protein kinase in a PI3K-dependent manner. Low concentrations of EtOH increased endothelial nitric-oxide synthase activity, which could be blocked by transfection of
HUVEC with dominant-negative Akt, implicating the PI3K/Akt pathway in this effect. The adenosine A1 receptor antagonist
1,3-dipopylcyclopentylxanthine prevented the phosphorylation of Akt
observed in the presence of EtOH, adenosine, or the A1 agonist
N6-cyclopentyladenosine. Incubation of HUVEC
with 50-100 mM EtOH resulted in mitochondrial permeability
transition and caspase-3 activation followed by apoptosis, as
documented by DNA fragmentation and TUNEL assays. EtOH-induced
apoptosis was unaffected by DPCPX and was potentiated by wortmannin or
LY294002. We conclude that treatment with low concentrations of EtOH
activates the cell survival promoting PI3K/Akt pathway in endothelial
cells by an adenosine receptor-dependent mechanism and
activation of the proapoptotic caspase pathway by higher concentrations
of EtOH via an adenosine-independent mechanism can mask or counteract
such effects.
 |
INTRODUCTION |
Alcohol has been the most widely used and misused drug throughout
human history. Aside from its well known neurobehavioral effects,
alcohol also influences cardiovascular variables. The ingestion of one
or two alcohol-containing drinks has acute effects on heart rate, blood
pressure, cardiac output, myocardial contractility, and regional blood
flow (1), actions that are generally not clinically important. During
the last few decades, moderate alcohol consumption has been associated
with a reduced risk for ischemic cardiovascular disease (2, 3), whereas
chronic heavy drinking was found to increase cardiovascular morbidity
and mortality (3). Although the cardioprotective effect of moderate
drinking is generally attributed to an elevation of high density
lipoproteins and reduced platelet aggregation (4), alcohol has been
shown to alter endothelial function (5); such changes may also
contribute to its cardioprotective effects. Vascular endothelial cells,
because of their location at the interface of blood and the vessel
wall, are susceptible to the influence of various blood-borne agents.
The endothelium is now recognized as an important regulator of vascular
tone, and the controlled proliferation of vascular endothelial cells is
a key step in angiogenesis. In the present study we examined the
hypothesis that ethanol may influence both pro- and antiapoptotic pathways in the vascular endothelium in ways that could contribute to
its dose-dependent effects on cardiovascular morbidity.
The serine/threonine protein kinase Akt was originally discovered as
the cellular homolog (c-Akt) of the transforming retrovirus AKT8 (6).
It is a novel kinase with similarities to both protein kinase C and
protein kinase A, so it is also referred to as protein kinase B (7).
Akt is a downstream mediator of phosphatidylinositol 3-kinase
(PI3K),1 recruited to the
plasma membrane by binding the lipid products of PI3K,
phosphatidylinositol 3,4-bisphosphate and 3,4,5-trisphosphate, which bind to the pleckstrin homology domain present in a number of
cytosolic signaling proteins including Akt (8). Akt is a multifunctional mediator of PI3K-dependent signaling and
functions to promote cell survival as well as the transcription and
translation of proteins involved in cell cycle progression (9).
Receptor-induced activation of Akt is blocked by PI3K inhibitors and by
the expression of dominant-negative forms of PI3K (10-17).
Phosphorylated Akt activates different downstream effectors, including
endothelial nitric-oxide synthase (eNOS), an enzyme involved in
vascular remodeling and angiogenesis and also responsible for
maintaining systemic blood pressure (18, 19). Another major downstream
effector is p70S6 kinase, which phosphorylates the ribosomal S6 protein
in response to stimulation with mitogens and preferentially increases
the translation of mRNAs containing 5'-terminal oligopolypyrimidine
tracts (14, 20). Glycogen synthase kinase 3 (GSK-3) is also a target of
Akt (13, 21-25). Inhibition of GSK-3 by Akt inhibits apoptosis and
promotes cell survival (22, 26). Akt is well established as a mediator
of cell survival, as its activation protects against apoptosis induced by withdrawal of growth factor or serum (27). NF- B is a downstream mediator of Akt in anti-apoptotic signaling (28). When bound to its
cytosolic inhibitor, I B, NF- B is sequestered in the cytoplasm. Upon its phosphorylation by I B kinases, I B is degraded, which allows NF- B to move to the nucleus and activate the transcription of
anti-apoptotic proteins (29).
Here we report that in the presence of low concentrations (2-20
mM) of ethanol, the cell survival-promoting PI3K/Akt
pathway and several of its downstream effectors, including eNOS, GSK-3, p70S6 kinase, and NF- B, are activated via an
adenosine-dependent mechanism, whereas at concentrations of
50-100 mM, ethanol promotes serum deprivation-induced
endothelial cell apoptosis independently of adenosine by activating
caspase-3 and its downstream target, PARP-1. These
dose-dependent, opposing effects on endothelial cell
survival pathways may contribute to the bimodal effects of ethanol
consumption on cardiovascular morbidity.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Ethanol, pertussis toxin (PTX), GF 109203X,
wortmannin, and LY294002,
N6-cyclopentyladenosine (CPA),
1,3-dipopylcyclopentylxanthine (DPCPX), and adenosine were purchased
from Sigma. Rabbit anti-human antibodies to native and
phosphorylated forms of Akt (Ser-473; catalog No. 9272 and 9271),
I B- (catalog No. 9242 and 9246), GSK-3 / (Ser-219; catalog
No. 9331), p70S6 kinase (catalog No. 9205), p44/42 MAP kinase (catalog
No. 9102 and 9101), and caspase-3 (catalog No. 9662) were purchased
from New England Biolabs (Beverly, MA). Anti-poly(ADP-ribose) polymerase (PARP; catalog no. SA-253) and caspase-3 cellular activity assay kits were purchased from Biomol (Plymouth Meeting, PA). Anti-rabbit IgG (horseradish peroxidase-linked) and enhanced
chemiluminescence reagent (ECL) detection system were obtained from
PerkinElmer Life Sciences. [35S]GTP S was purchased
from PerkinElmer Life Sciences, and [ -32P]ddATP was
obtained from Amersham Biosciences. TdT recombinant was purchased from Invitrogen.
Cell Culture--
Primary cultured human umbilical vein
endothelial cells (HUVEC) were purchased from ATCC. The plastic culture
flask was precoated with 0.2% gelatin for at least 1 h prior to
seeding the cells. HUVEC were maintained in EBM-2 medium (Clonetics)
supplemented with 2% fetal bovine serum and growth factors such as
hydrocortisone, hFGF-B, VEGF, R3-IGF-1, ascorbic acid,
hEGF, GA-1000, and heparin plus 100 units/ml penicillin and 100 µg/ml
streptomycin in a humidified atmosphere of 5% CO2 at
37 °C. All experiments were performed using HUVEC at 2-4 passages,
with no cells being used beyond the fourth passage. For serum
starvation, the regular medium was removed and replaced with medium 199.
Western Blot Analyses--
Western immunoblotting was done as
previously described (30). HUVEC cells were cultured in serum-free
medium overnight, prior to the addition of ethanol, to reduce the basal
levels of Akt phosphorylation. Cell lysate protein (60 µg) from an
equal number of cells was size-fractionated by 10% SDS-PAGE and then transferred electrophoretically to a nitrocellulose membrane. The
membrane was blocked by incubation for 2 h in TPBS buffer (1×
PBS, 0.1% Tween 20) containing 5% (w/v) nonfat dry milk at room
temperature and then immunoblotted with primary antibody (at 1:1000
dilution in TPBS plus 3% bovine serum albumin) overnight at 4 °C
and horseradish peroxidase-conjugated secondary antibody (1:2000 in
blocking buffer) for 2 h at room temperature. Immunoreactive bands
were visualized using an ECL detection system.
[35S]GTP S Binding--
Confluent HUVEC were
rinsed twice in PBS and harvested by scraping. The cells were then
homogenized in TME-Na buffer (50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA, 100 mM NaCl, pH 7.4), and the homogenate was centrifuged at
48,000 × g for 20 min at 4 °C. The pellet was
resuspended in TME-Na, homogenized, and adjusted to a protein
concentration of 1 µg/µl with TME-Na. The membrane homogenate was
then used for measuring agonist-stimulated [35S]GTP S
binding according to Griffin et al. (31). HUVEC membranes (100 µg) were incubated in TME-Na buffer containing 0.1 mg/ml bovine
serum albumin with 30 µM GDP, 0.1 nM
[35S]GTP S, and different concentrations of ethanol in
silanized glass tubes with or without 100 ng/ml PTX or 100 nM DPCPX. The total assay volume was 0.5 ml, and triplicate
aliquots were incubated at 30 °C for 1 h. The reaction was
terminated by the addition of 2 ml of ice-cold wash buffer (50 mM Tris-HCl, pH 7.4) followed by vacuum filtration
through glass fiber (type B) filters. Filters were rinsed three
more times with wash buffer, and the retained radioactivity was
determined by liquid scintillation spectrometry. Basal binding was
assayed in the absence of ethanol and in the presence of GDP.
Transfections and Fluorescent Cell Sorting--
Plasmids
pEGFP-N1 (CLONTECH) and dominant-negative Akt were
co-transfected into HUVEC P2 cells. Using an initial seeding density of 1 × 104 cells/cm2, HUVEC were ready
for transfection at 18-24 h post-seeding. For each 75-cm2
flask of cells to be transfected, 30 µl of Lipofectin and 5 µg of
each DNA were diluted separately in 500 µl of Opti-MEM I reduced serum medium. Solutions were combined, gently mixed, and incubated for
45 min at room temperature to allow formation of DNA-lipid complexes.
The normal medium was replaced with 8 ml of Opti-MEM I reduced medium,
and the DNA-lipid complexes were added subsequently to each flask and
mixed gently by rocking the plate back and forth. Cells were incubated
for 3 to 4 h at 37 °C in humidified air in 5% CO2.
The transfection mixture was replaced with basal media containing
supplements. Transfected cells were identified by cell sorting at
18-24 h post-transfection, and only the positive cells were used for
the eNOS activity assay.
eNOS Activity--
eNOS activity was measured by monitoring the
conversion of L-[3H]arginine to
L-[3H]citrulline (eNOSdetect Assay Kit,
Stratagene). Cells were trypsinized and washed with PBS and lysed in an
adequate volume of homogenization buffer (25 mM Tris-HCl,
pH 7.4, 1 mM EDTA, 1 mM EGTA). The supernatant was separated from the homogenate, and protein concentration was adjusted to 5 µg/µl. The reaction mixture was prepared on ice by
adding the following components: 25 µl of 2 reaction buffer (50 mM Tris-HCl, pH7.4, 6 µM BH4, 2 µM flavin adenine dinucleotide, 2 µM flavin
adenine mononucleotide), 5 µl of 10 mM NADPH (freshly prepared in 10 mM Tris-HCl, pH 7.4), 1 µl of
[3H]arginine (50 µCi/ml), 5 µl of 6 mM
CaCl2, and 4 µl of H2O. The reaction was
initiated by the addition of 10 µl of protein extract (total volume
of 50 µl) and carried out for 30 min at 37 °C. Rat cerebellum
extract and N -nitro-L-arginine methyl ester HCl were used as positive or inhibitory control. The reaction was terminated by
the addition of 400 µl of stop buffer containing 50 mM
HEPES, pH 5.5, and 5 mM EDTA. The reaction mixture was then
passed through a provided resin. The [3H]citrulline
generated was quantified by liquid scintillation spectrometry.
Luciferase Reporter Assay--
The NF- B luciferase promoter
construct was purchased from Stratagene. Transient transfection was
performed as described above. The transfection mixture was replaced
with medium M199 overnight. Cells were stimulated for another 8 h
with ethanol and then washed twice with PBS and lysed in 200 µl (for
12-well culture plate) of 1× passive lysis buffer. Cell lysates were
centrifuged for 30 s at top speed in a refrigerated
microcentrifuge, the cleared lysates were transferred to a fresh tube,
and protein content was determined. Equal amounts of protein were used
for reporter enzyme analyses using the Luciferase Reporter Assay System
(Promega) and a luminometer.
Flow Cytometric Analysis of Apoptosis by Measurement of
Mitochondrial Transmembrane Potential ( m) and the
Generation of Reactive Oxygen Species (ROS)--
 m
and ROS generation were measured according to (32). HUVEC were treated
with or without ethanol for 6 h under standard conditions and
harvested by trypsinization.  m was measured directly by using 40 nM 3,3'-dihexyloxacarbocyanine (DiOC6 (3),
Molecular Probes, Eugene, OR). Fluorescence was measured after staining the cells for 15 min at 37 °C. To assess ROS generation by flow cytometry, cells were treated with 2 µM hydroethidine
(Molecular Probes) for 15 min at 37 °C. The probes were excited with
a laser at 488 nm (250 milliwatts), and emission was measured
through a 530/30 nm (DiOC6 (3)) or a 575/26 nm (ethidium)
bandpass filter. Logarithmic amplification was used to detect the
fluorescence of the probes.
DNA Fragmentation Assay--
Following treatment, DNA was
isolated using a DNA Isolation Kit (Gentra, Minneapolis, MN). Briefly,
300 µl of cell lysates were incubated with 1.5 µl of RNase A
solution at 37 °C for 5 min. 100 µl of protein precipitation
solution was added to each sample, and after centrifugation at
13,000 × g for 1 min, the supernatant containing the
DNA was precipitated by 300 µl of isopropanol and washed by 70%
ethanol. DNA pellets were rehydrated using DNA hydration solution and
incubated at 65 °C for 1 h. DNA was end-labeled with 0.5 µCi of [ -32P]ddATP using 25 units of terminal
transferase enzyme at 37 °C for 1 h. The reaction was
terminated by the addition of EDTA (pH 8.0) to a final concentration of
25 mM. Labeled DNA was separated from unincorporated
radionucleotide by chroma-spin columns (CLONTECH) by agarose gel electrophoresis. The gel was transferred onto Whatman No. 3MM chromatography paper, dried, and analyzed by phosphorimaging (Typhoon, Molecular Dynamics).
TUNEL Assay--
A TUNEL apoptosis detection kit (Upstate
Biotechnology Inc.) was used for DNA fragmentation fluorescence
staining according to the manufacturer's protocol. In brief, following
treatment the cells were fixed with 4% paraformaldehyde in 0.1 M NaH2PO4, pH 7.4, and incubated
with a reaction mix containing biotin-dUTP and terminal
deoxynucleotidyl transferase for 60 min. Fluorescein-conjugated avidin
was applied to the sample, which was then incubated in the dark
for 30 min. Positively stained fluorescein-labeled cells were
visualized and photographed by fluorescence microscopy.
Measurement of Caspase-3 Activity--
Caspase-3 activity was
measured using a colorimetric assay kit (Biomol, Plymouth Meeting, PA)
according to the manufacturer's protocol. Cell lysates were
centrifuged at 10,000 × g for 10 min at 4 °C and
their protein content determined (Bio-Rad). Equal amounts of cell
lysates were incubated with Ac-DEVD-p nitroanilide substrate
at 37 °C, and the absorbance at 405 nm was measured in a microtiter
plate reader. The kinetic curve was obtained by recording data at
10-min intervals for 4 h.
Data Analysis--
Data are reported as means ± S.E. of at
least three separate experiments, each performed in triplicate.
Statistical significance was determined using Student's t test.
 |
RESULTS |
Ethanol Induces Phosphorylation of Akt in HUVEC--
A blood
alcohol level of 0.1%, the legal limit for driving in many states, is
equivalent to ~22 mM ethanol. The ethanol concentrations used in this study were 10 µM-100 mM, which
spans the range of behaviorally sub-threshold to severe intoxicating
levels. Ethanol treatment caused strong,
concentration-dependent activation of Akt in HUVEC (Fig.
1A), activation being evident
in the presence of as little as 10 µM ethanol. The time
course is illustrated in Fig. 1B, with activation beginning
at 5 min after the addition of ethanol and peaking at 30 min.
Furthermore, the time- and concentration-dependent activation of Akt was evident both in the absence (upper
panels) and in the presence of serum and growth factors
(lower panels). Additionally, activation of Akt following
ethanol treatment was completely antagonized by two structurally
dissimilar inhibitors of PI3K, wortmannin and LY294002 (Fig.
1C); the ethanol metabolite acetaldehyde was inactive in
this pathway (Fig. 1D).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 1.
Ethanol treatment increases Akt
phosphorylation in HUVEC. HUVEC were incubated with various
concentrations of EtOH for 30 min (A) or with 20 mM ethanol for the indicated time periods (B)
under serum-starved condition (upper panels) or in
serum-containing medium (lower panels). C,
serum-starved HUVEC were preincubated for 30 min with 100 nM wortmannin (Wort.) or 25 µM
LY294002 (LY) prior to the addition of 10 mM
ethanol for another 30 min. D, serum-starved cells were
treated with 10 mM EtOH, 10 µg/ml insulin (as positive
controls), or 200 µM acetaldehyde (Acet.) for
30 min. Cell extracts from panels A-D were subjected to
Western blot analysis by using anti-phospho-Akt and anti-Akt antibodies
as described under "Experimental Procedures."
|
|
Ethanol Induces MAP Kinase Activation in a
PI3K-dependent Manner--
Since the p44/42 MAP kinase can
be activated by PI3K (33), we tested whether ethanol treatment can
activate MAP kinase in HUVEC. As illustrated in Fig.
2A, treatment with 20 mM ethanol results in rapid phosphorylation of MAP kinase
within 5 min, an effect that is abrogated in the presence of the PI3K
inhibitors wortmannin or LY294002 (Fig. 2B).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 2.
Ethanol activates MAP kinase through a
PI3K-dependent mechanism. A, phosphorylated
p44/42 MAP kinase was visualized by Western blotting as described under
"Experimental Procedures." Serum-starved HUVEC were
incubated with or without 20 mM ethanol for the indicated
times. B, cells were preincubated for 30 min with 100 nM wortmannin (Wort.) or 25 µM
LY294002 (LY) prior to the addition of 20 mM
ethanol for another 5 min.
|
|
Ethanol Induces Akt Activation by a PTX-sensitive G
Protein-dependent Mechanism--
To explore the mechanism
by which ethanol treatment induces PI3K/Akt activation, we examined the
effect of ethanol on GTP S binding in HUVEC membranes. As shown in
Fig. 3A, in the presence of
2-100 mM ethanol GTP S binding in HUVEC membranes was
increased by up to 25%. This effect was largely inhibited by PTX, a
Gi/o protein inhibitor, or by DPCPX, an A1 adenosine
receptor inhibitor. This indicates the possible involvement of
Gi/o protein(s) and A1 adenosine receptors in the
activation of Akt phosphorylation by ethanol treatment. The mechanisms
involved in Akt phosphorylation were further examined by Western blot
analyses. As shown in Fig. 3B, Akt phosphorylation in
response to ethanol treatment was largely inhibited by PTX but not by
GF 109203X, a protein kinase C inhibitor.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
Ethanol activates phosphorylation of Akt in
HUVEC by a Gi/o protein-dependent
mechanism. A, [35S]GTP S binding was
measured in membrane preparations from HUVEC as described under
"Experimental Procedures." *, in the right panel,
indicates significant difference (p < 0.05) from
values with EtOH alone. B, serum-starved cells were
preincubated for 50 min with 100 ng/ml PTX or 2 µM GF
109203X prior to the addition of 10 mM ethanol for another
30 min. Cell extracts were then prepared and subjected to Western blot
analysis using anti-phospho-Akt and anti-Akt antibodies.
|
|
Activation of Downstream Effectors of Akt by Ethanol
Treatment--
We next investigated ethanol activation of pathways
downstream of Akt. As shown in Fig.
4A, p70S6 kinase,
GSK-3 / , and I B- can all be phosphorylated by treatment with
10 mM ethanol. Further experiments with transfected NF- B
promoter/luciferase constructs indicated NF- B promoter activity was
increased by up to 3-fold in the presence of 2-20 mM
ethanol, but with higher concentration of ethanol (50 mM)
the activity declined (Fig. 4B). Similar results have been
obtained for eNOS activity (Fig. 5). The
increase in eNOS activity was dependent on ethanol concentration and on
the duration of ethanol exposure. A time course study showed that eNOS
activity peaked at 10 min following ethanol exposure (Fig. 5A). eNOS activity in HUVEC was increased by treatment with
20 mM ethanol, but activity declined toward basal levels
with increasing ethanol concentrations (Fig. 5B). This
ethanol-induced increase in eNOS activity could be blocked by
transfection of HUVEC cells with dominant-negative Akt, implicating the
PI3K/Akt pathway in eNOS activation by ethanol (Fig. 5C).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 4.
Downstream effectors of Akt phosphorylated by
ethanol treatment. A, HUVEC were treated with 10 mM of ethanol for various time periods. Cell extracts were
then subjected to Western blotting analysis using anti-phospho-p70S6
kinase, anti-phospho-glycogen synthase kinase 3 / (pGSK
3 / ), anti-phospho-I B- , and anti-I B- antibodies.
The anti-phosphoprotein antibodies used are directed against epitopes
known to be involved in the activation of the proteins. B,
HUVEC cells were transiently transfected with NF- B
promoter/luciferase construct. After 18 h, 2-50 mM
ethanol was added for another 8 h. Cell extracts were prepared and
luciferase activities were measured. Values are means ± S.E. from
three independent experiments, expressed as fold changes over control.
*, indicates significant difference (p < 0.05) from
ethanol-free control.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 5.
Ethanol treatment activates eNOS by an
Akt-dependent mechanism. HUVEC were treated with 20 mM ethanol for various time points (A) or
with various concentrations of ethanol for 10 min (B). eNOS
activity was measured in cell extracts as described under
"Experimental Procedures." C, plasmids pEGFP-N1 and
dominant-negative Akt were cotransfected into HUVEC as described under
"Experimental Procedures." Transfected cells were identified and
sorted by flow cytometry and were then treated with buffer
(Control) or 20 mM ethanol for 10 min before
measuring eNOS activity. Values are the means ± S.E. from three
independent experiments.
|
|
Ethanol Treatment Activates Akt by an A1 Adenosine
Receptor-dependent Mechanism--
It has been shown that
some effects of ethanol are mediated by endogenous adenosine (34-37)
and that adenosine activates Akt (38, 39). We wondered whether ethanol
activated Akt in HUVEC by an adenosine receptor-dependent
mechanism. As shown in Fig. 6, incubation
of HUVEC with adenosine or the selective A1 adenosine receptor agonist
CPA results in increased phosphorylation of Akt. Furthermore,
pretreatment of HUVEC with the selective A1 receptor antagonist DPCPX
almost completely prevented the increased Akt phosphorylation caused by
ethanol, adenosine, or CPA, which implicates adenosine in this effect
of ethanol.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
Ethanol treatment stimulates Akt
phosphorylation by an A1 adenosine receptor-dependent
mechanism. HUVEC were pretreated with or without 100 nM DPCPX for 30 min, followed by 30-min incubation with 20 mM EtOH, 10 µM adenosine (Ad), or
1 µM CPA as indicated. Cell extracts were then subjected
to Western blotting using anti-phospho-Akt and anti-Akt
antibodies.
|
|
High Concentrations of Ethanol Induce Apoptosis Independently of
Adenosine--
Fetal alcohol syndrome induced by maternal drinking has
been linked to apoptotic cell death in the central nervous system. Therefore, we tested whether treatment with high concentrations of
alcohol can also lead to apoptosis in vascular endothelial cells.
Because there is increasing evidence that altered mitochondrial function is linked to apoptosis (40, 41), we first checked the
ability of ethanol treatment to induce a mitochondrial permeability transition (MPT) state as an apoptotic early event, by measuring  m and ROS generation. We measured  m
by monitoring the incorporation of the fluorescent probe
DiOC6 (3) into mitochondria, which is driven by the
 m (42-44). Control cells exposed to
DiOC6 (3) exhibited bright DiOC6 (3)
fluorescence, and exposing them to 50 mM ethanol resulted
in a decrease in DiOC6 (3) fluorescence in 76% of the
cells. Since a low m is associated with altered mitochondrial function, we also determined whether exposure to 50 mM ethanol potentiated mitochondrial
O generation by the oxidative
conversion of hydroethidine to ethidium. We noted that 5% of the cells
exhibited an increase in ethidium fluorescence. As illustrated in Fig.
7, discrete cell populations shifted from
the right lower quadrant to the left lower and
left upper quadrants. Taken together, treatment with 50 mM ethanol not only resulted in a loss of m
but also led to uncoupling of oxidative metabolism and to the
generation of ROS in HUVEC cells as early as only 6 h of
incubation. No significant changes in fluorescence have been noted in
the presence of lower concentration (2-20 mM) of ethanol
(data not shown).

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 7.
Ethanol-induced alterations in
 m and ROS generation in
HUVEC. Confluent HUVEC were incubated without (A) or
with 50 mM ethanol (B) for 6 h under normal
conditions. Cells were then stained with DiOC6 (3) and
hydroethidine (HE) to measure  m and ROS
generation, respectively. Control cells are shown as a discrete
population exhibiting bright DiOC6 (3) fluorescence and dim
ethidium fluorescence (lower right quadrant). Ethanol (50 mM) decreased  m, as demonstrated by a
reduction in DiOC6 (3) fluorescence (lower left
quadrant), and increased ROS generation, as indicated by an
increase in ethidium fluorescence (upper left
quadrant).
|
|
We next analyzed DNA fragmentation following exposure of HUVEC to
ethanol and wortmannin (Fig.
8A). Incubation of HUVEC under conditions of serum and growth factor deprivation for 24 h
caused a minority of the cells to undergo apoptosis as verified
by a slight increase in DNA fragmentation compared with control.
Exposure of serum-deprived HUVEC to 2-10 mM of ethanol did
not significantly alter the levels of DNA fragmentation (Fig.
8A) and cell apoptosis (Fig. 8B). However, cells
exposed to 50 mM ethanol displayed a dramatic increase in
DNA fragmentation (Fig. 8A) and cell apoptosis (Fig.
8B). Moreover, incubation of serum-deprived HUVEC with 100 nM wortmannin, a PI3K inhibitor, also caused an increase in
DNA fragmentation without influencing the ethanol-induced increase (Fig. 8A) and also increased cell apoptosis (Fig.
8B). This indicates that the PI3K/Akt pathway has a
protective effect on cell survival. Finally, the selective adenosine A1
receptor antagonist DPCPX did not block 50 mM
ethanol-induced apoptosis. Similar results were obtained by
measuring the activity of caspase-3, an executioner of apoptosis that
has been shown to mediate apoptosis in mammalian cells. As shown in
Fig. 9A, serum starvation
caused an increase in caspase-3 activity, which was not affected by 2 mM ethanol but was markedly potentiated by 20-50
mM ethanol treatment. Consistent evidence was obtained by
immunoblotting, showing a significantly increased level of the active
17-kDa subunit of caspase-3 and increased cleavage of the 85-kDa PARP
(Fig. 9B) in serum-deprived HUVEC exposed to 20-50
mM ethanol.

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 8.
High concentrations of ethanol induce
apoptosis in HUVEC. Serum-starved HUVEC were treated with or
without wortmannin (Wort.) or DPCPX for 30 min followed by
incubation with various concentrations of EtOH for 30 min as indicated.
Cells were then harvested for DNA fragmentation analysis (A)
or TUNEL assay (B) as described under "Experimental
Procedures."
|
|

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 9.
High but not low concentrations of ethanol
induce caspase-3 and PARP activation. Serum-starved HUVEC were
incubated with various concentrations of ethanol for 24 h; cell
extracts were then prepared and subjected to caspase-3 activity assay
(A) or Western blotting using anti-caspase-3 and anti-PARP
antibodies (B) as described under "Experimental
Procedures." GF, growth factors.
|
|
 |
DISCUSSION |
The present findings document a bimodal action of ethanol on
pathways involved in endothelial cell survival. At concentrations up to
20 mM that do not cause significant intoxication in
vivo, ethanol was found to activate the PI3K/Akt cell survival
pathway in cultured human vascular endothelial cells. Consistent with this activation, several key downstream effectors of Akt known to be
linked to anti-apoptotic, cell survival-promoting effects were also
activated. In contrast, at concentrations of 50-100 mM,
which cause severe intoxication in vivo, ethanol activated the pro-apoptotic caspase-3/PARP-1 pathway and apoptosis, which is
analogous to its pro-apoptotic effect in the central nervous system. To
best interpret these findings, we propose a model in Fig.
10 that may partly explain the bimodal
action of ethanol in the cardiovascular system.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 10.
Bimodal action of ethanol on HUVEC. See
text for further explanation. AT, adenosine
transporter; A1 R, adenosine A1 receptor.
|
|
In this model, treatment with low concentrations (<20 mM)
of ethanol elicit activation of Akt and its downstream effectors including NF- B and eNOS. Some of these effectors, such as the p70S6
kinase, can also be activated by MAP kinase (33), and we found that
ethanol rapidly activates MAP kinase in a PI3K-dependent manner (Fig. 2). It has been clearly shown that activation of Akt,
eNOS, and NF- B play an important role in promoting angiogenesis and
inhibiting apoptosis in HUVEC (27-29, 45). Importantly, the effects
of ethanol treatment on Akt phosphorylation were evident not only in
serum-starved cells but also in the presence of physiological levels of
serum and growth factors, which suggests that similar changes are
likely present in the intact organism. Thus, activation of Akt by low
concentrations of ethanol likely promotes endothelial cell survival and
thus may contribute to the protective effect of moderate alcohol
drinking against cardiovascular morbidity.
Furthermore, we provided evidence suggesting that ethanol activates Akt
by an adenosine receptor-dependent mechanism. Adenosine is
a signaling molecule that is released from tissue, including endothelial cells, in response to hypoxia, ischemia, or inflammation (46). The released adenosine can then act in an autocrine or paracrine
fashion on G protein-coupled adenosine receptors to protect tissue from
injury (47). Of the different adenosine receptor subtypes, A1 and A3
receptors are coupled to Gi/Go and A1 receptors
(which are present in vascular endothelial cells (47)) and have
been linked to activation of the PI3K/Akt pathway (38). The
receptor-mediated effects of adenosine are terminated by uptake into
cells by facilitated diffusion via the nucleoside transporter (48). The
finding that a selective A1 receptor antagonist, DPCPX, was able to
inhibit the increase in Akt phosphorylation induced by ethanol
treatment, adenosine, or the selective A1 agonist CPA strongly suggests
that ethanol activates Akt in HUVEC by an adenosine
receptor-dependent mechanism. However, the mechanism by
which exposure to ethanol leads to adenosine receptor activation is not
clear. It has been shown that acute ethanol treatment increases the
extracellular level of adenosine by inhibiting adenosine uptake via the
transporter in NG108-15 cells (49), S49 lymphoma cells (50), and
hippocampal brain slices (51). A similar mechanism in HUVEC may account
for the observed inhibition by DPCPX of EtOH-induced Akt
phosphorylation. Further studies will be required to confirm this possibility.
In addition to activation of Akt, high concentrations (>20
mM) of ethanol also induce MPT, followed by activation of
caspase-3 and apoptosis in HUVEC, which may counteract the
anti-apoptotic effects of Akt activation. These opposing effects are
distinguished not only by their differential sensitivity to ethanol but
also by the differential involvement of adenosine. Unlike the
adenosine-mediated activation of Akt, the pro-apoptotic effect of
high concentrations of ethanol is independent of adenosine as well as
Akt, as indicated by its resistance to inhibition by DPCPX or
wortmannin. Mitochondria play a key role in the pathways of cell death
(52). Mitochondrial damage not only causes "loss of function"
resulting in a bioenergetic defect but also regulates effector
mechanisms involving cytochrome c release into the cytosol
(53). Cytosolic cytochrome c binds to Apaf-1 (the mammalian
CED-4 homolog) and dATP, resulting in the recruitment and activation of
procaspase-9. Activated caspase-9 then proteolytically activates
caspase-3 (54). Thus, exposure of HUVEC to high concentrations of
ethanol triggers the cascade of MPT followed by activation of caspase-3
and apoptosis. Mitochondria are known targets of ethanol in various
types of cells, including hepatocytes (40) and neuronal cells (41), but
the molecular mechanisms by which ethanol initiates the MPT are
currently unknown.
Several mechanisms have been implicated in the cardioprotective effect
of moderate alcohol drinking. These include modulation of blood
lipoproteins (55), reduced platelet activation and thrombosis (55), and
activation of protein kinase C (56). Inhibition of the
synthesis of the vasoconstrictor peptide endothelin-1 by components of
red wine may account for the added benefits accrued from drinking red
wine (57).
The results of the present study suggest that, in addition to these
mechanisms, ethanol induction of Akt activation may also contribute to
the cardiovascular protective effect of moderate alcohol drinking. Akt
phosphorylation results in the activation of a number of downstream
effectors implicated in cell survival and also in the inhibition of
apoptotic pathways, as suggested by the finding that the PI3K inhibitor
wortmannin potentiates apoptosis in HUVEC. Together, these effects
could promote angiogenesis induced by moderate hypoxia and would thus
contribute to the protective effects of moderate drinking in ischemic
heart disease.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
On leave from the Institute of Immunology, University of Science
and Technology of China, Hefei 230027, China.
§
To whom correspondence should be addressed: National Institute on
Alcohol Abuse and Alcoholism, National Institutes of Health, 12420 Parklawn Dr., Rm. 120, MSC-8115, Bethesda, MD 20892-8115. Tel.:
301-443-2069; Fax: 301-480-0257; E-mail: gkunos@mail.nih.gov.
Published, JBC Papers in Press, March 27, 2002, DOI 10.1074/jbc.M110712200
 |
ABBREVIATIONS |
The abbreviations used are:
PI3K, phosphatidylinositol 3-kinase;
MAP, mitogen-activated protein;
GSK, glycogen synthase kinase;
eNOS, endothelial nitric-oxide synthase;
PTX, pertussis toxin;
CPA, N6-cyclopentyladenosine;
DPCPX, 1,3-dipopylcyclopentylxanthine;
GTP S, guanosine
5'-3-O-(thio)triphosphate;
MPT, mitochondrial permeability
transition;
TUNEL, terminal deoxynucleotidyltransferase-mediated dUTP
nick end-labeling;
PARP, poly(ADP-ribose) polymerase;
HUVEC, human
umbilical vein endothelial cells;
PBS, phosphate-buffered saline;
ROS, reactive oxygen species;
DiOC6, 3,3'-dihexyloxacarbocyanine.
 |
REFERENCES |
| 1.
|
Kunos, G.,
and Varga, K.
(1996)
NIAAA Res. Monogr.
31,
243-261
|
| 2.
|
Tansescu, M., Hu, F. B.,
Willett, W. C.,
Stampfer, M. J.,
and Rimm, E. B.
(2001)
J. Am. Coll. Cardiol.
38,
1836-1842[Abstract/Free Full Text]
|
| 3.
|
Van Tol, A.,
and Hendriks, H. F.
(2001)
Curr. Opin. Lipidol.
12,
19-23[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Constant, J.
(1997)
Coron. Artery Dis.
8,
645-649[Medline]
[Order article via Infotrieve]
|
| 5.
|
Davda, R. K.,
Chandler, L. J.,
Crews, F. T.,
and Guzman, N. J.
(1993)
Hypertension
21,
939-943[Abstract/Free Full Text]
|
| 6.
|
Staal, S. P.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
5034-5037[Abstract/Free Full Text]
|
| 7.
|
Jones, P. F.,
Jakubowicz, T.,
Pitossi, F. J.,
Maurer, F.,
and Hemmings, B. A.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
4171-4175[Abstract/Free Full Text]
|
| 8.
|
Bottomley, M. J.,
Salim, K.,
and Panayotou, G.
(1998)
Biochim. Biophys. Acta
1436,
165-183[Medline]
[Order article via Infotrieve]
|
| 9.
|
Vanhaesebroeck, B.,
and Aless, D. R.
(2000)
Biochem. J.
346,
561-576[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Franke, T. F.,
Yang, S. I.,
Chan, T. O.,
Datta, K.,
Kazlauskas, A.,
Morrison, D. K.,
Kaplan, D. R.,
and Tsichlis, P. N.
(1995)
Cell
81,
727-736[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Kohn, A. D.,
Kovacina, K. S.,
and Roth, R. A.
(1995)
EMBO J.
14,
4288-4295[Medline]
[Order article via Infotrieve]
|
| 12.
|
Alessi, D. R.,
Andjelkovic, M.,
Caudwell, B.,
Cron, P.,
Morrice, N.,
Cohen, P.,
and Hemmings, B. A.
(1996)
EMBO J.
15,
6541-6551[Medline]
[Order article via Infotrieve]
|
| 13.
|
Cross, D. A. E.,
Alessi, D. R.,
Cohen, P.,
Andjelkovic, M.,
and Hemmings, B. A.
(1995)
Nature
378,
785-789[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Burgering, B. M. T.,
and Coffer, P. J.
(1995)
Nature
376,
599-602[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
del Peso, L.,
Gonzales-Garcia, M.,
Page, C.,
Herrera, R.,
and Nunez, G.
(1997)
Science
278,
687-689[Abstract/Free Full Text]
|
| 16.
|
Reif, K.,
Burgering, B. M. T.,
and Cantrell, D. A.
(1997)
J. Biol. Chem.
272,
14426-14433[Abstract/Free Full Text]
|
| 17.
|
Scheid, M. P.,
and Duronio, V.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
7439-7444[Abstract/Free Full Text]
|
| 18.
|
Dimmeler, S.,
Fleming, I.,
Fisslthaler, B.,
Hermann, C.,
Busse, R.,
and Zeiher, A. M.
(1999)
Nature
399,
601-605[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Fulton, D.,
Gratton, J. P.,
McCabe, T. J.,
Fontana, J.,
Fujio, Y.,
Walsh, K.,
Franke, T. F.,
Papapetropoulos, A.,
and Sessa, W. C.
(1999)
Nature
399,
577-601
|
| 20.
|
Abraham, R. T.
(1998)
Curr. Opin. Immunol.
10,
330-336[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Hajduch, E.,
Alessi, D. R.,
Hemmings, B. A.,
and Hundal, H. S.
(1998)
Diabetes
47,
1006-1013[Abstract]
|
| 22.
|
Pap, M.,
and Cooper, G. M.
(1998)
J. Biol. Chem.
273,
19929-19932[Abstract/Free Full Text]
|
| 23.
|
Shaw, M.,
Cohen, P.,
and Alessi, D. R.
(1997)
FEBS Lett.
416,
307-311[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Ueki, K.,
Yamamoto-Honda, R.,
Kaburagi, Y.,
Yamauchi, T.,
Tobe, K.,
Burgering, B. M. T.,
Coffer, P. J.,
Komuro, I.,
Akanuma, Y.,
and Yazaki, Y.
(1998)
J. Biol. Chem.
273,
5315-5322[Abstract/Free Full Text]
|
| 25.
|
van Weeren, P. C.,
de Bruyn, K. M. T.,
de Vries Smits, A. M. M.,
van Lint, J.,
and Burgering, B. M. T.
(1998)
J. Biol. Chem.
273,
13150-13156[Abstract/Free Full Text]
|
| 26.
|
Gold, M. R.,
Scheid, M. P.,
Santos, L.,
Dang-Lawson, M.,
Roth, R. A.,
Matsuuchi, L.,
Duronio, V.,
and Krebs, D. L.
(1999)
J. Immunol.
163,
1894-1905[Abstract/Free Full Text]
|
| 27.
|
Madge, L. A.,
and Pober, J. S.
(2000)
J. Biol. Chem.
275,
15458-15465[Abstract/Free Full Text]
|
| 28.
|
Romashkova, J. A.,
and Makarov, S. S.
(1999)
Nature
401,
86-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Foo, S. Y.,
and Nolan, G. P.
(1999)
Trends Genet.
15,
229-235[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Liu, J.,
Gao, B.,
Mirshahi, F.,
Sanyal, A. J.,
Khanolkar, A. D.,
Makriyannis, A.,
and Kunos, G.
(2000)
Biochem. J.
346,
835-840[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Griffin, G.,
Tao, Q.,
and Abood, M. E.
(2000)
J. Pharmacol. Exp. Ther.
292,
886-894[Abstract/Free Full Text]
|
| 32.
|
Guo, T. L.,
Miller, M. A.,
Datar, S.,
Shapiro, I. M.,
and Shenker, B. J.
(1998)
Toxicol. Appl. Pharmacol.
152,
397-405[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Toker, A.
(2000)
Mol. Pharmacol.
57,
652-658[Free Full Text]
|
| 34.
|
Acevedo, C. G.,
Huambachano, A.,
Perez, E.,
Rojas, S.,
Bravo, I.,
and Contreras, E.
(1997)
Placenta
18,
387-392[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Fredholm, B. B.,
and Wallman-Johansson, A.
(1996)
Pharmacol. Toxicol.
79,
120-123[Medline]
[Order article via Infotrieve]
|
| 36.
|
Krauss, S. W.,
Ghirnikar, R. B.,
Diamond, I.,
and Gordon, A. S.
(1993)
Mol. Pharmacol.
44,
1021-1026[Abstract]
|
| 37.
|
Nagy, L. E.,
Diamond, I.,
and Gordon, A. S.
(1991)
Mol. Pharmacol.
40,
812-817[Abstract]
|
| 38.
|
Germack, R.,
and Dickenson, J. M.
(2000)
Br. J. Pharmacol.
130,
867-874[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Takasuga, S.,
Katada, T., Ui, M.,
and Hazeki, O.
(1999)
J. Biol. Chem.
274,
19545-19550[Abstract/Free Full Text]
|
| 40.
|
Higuchi, H.,
Adachi, M.,
Miura, S.,
Gores, G. J.,
and Ishii, H.
(2001)
Hepatology
34,
320-328[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
de la Monte, S. M.,
and Wands, J. R.
(2001)
Alcohol. Clin. Exp. Res.
25,
898-907[Medline]
[Order article via Infotrieve]
|
| 42.
|
Kroemer, G.
(1997)
Nat. Med.
3,
614-620[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Marchetti, P.,
Hirsch, T.,
Zamzami, N.,
Castedo, M.,
Decaudin, D.,
Susin, S. A.,
Masse, B.,
and Kroemer, G.
(1996)
J. Immunol.
157,
4830-4836[Abstract]
|
| 44.
|
Kroemer, G.,
Petit, P.,
Zamzami, N.,
Vayssiere, J.,
and Mignotte, B.
(1995)
FASEB J.
9,
1277-1287[Abstract]
|
| 45.
|
Datta, S. R.,
Brunet, A.,
and Greenberg, M. E.
(1999)
Genes Dev.
13,
2905-2927[Free Full Text]
|
| 46.
|
Bouma, M. G.,
van den Wildenberg, F. A.,
and Buurman, W. A.
(1996)
Am. J. Physiol.
270,
C522-C529[Medline]
[Order article via Infotrieve]
|
| 47.
|
Linden, J.
(2001)
Annu. Rev. Pharmacol. Toxicol.
41,
775-787[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Jarvis, M. F.,
and Williams, M.
(1988)
Pharmacol. Biochem. Behav.
30,
707-714[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Sapru, M. K.,
Diamond, I.,
and Gordon, A. S.
(1994)
J. Pharmacol. Exp. Ther.
271,
542-548[Abstract/Free Full Text]
|
| 50.
|
Nagy, L. E.,
Diamond, I.,
Casso, D. J.,
Franklin, C.,
and Gordon, A. S.
(1990)
J. Biol. Chem.
265,
1946-1951[Abstract/Free Full Text]
|
| 51.
|
Diao, L.,
and Dunwiddie, T. V.
(1996)
J. Pharmacol. Exp. Ther.
278,
542-546[Abstract/Free Full Text]
|
| 52.
|
Green, D. R.,
and Reed, J. C.
(1998)
Science
281,
1309-1312[Abstract/Free Full Text]
|
| 53.
|
Liu, X.,
Kim, C. N.,
Yang, J.,
Jemmerson, R.,
and Wang, X.
(1996)
Cell
86,
147-157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Zou, H.,
Henzel, W. J.,
Liu, X.,
Lutschg, A.,
and Wang, X.
(1997)
Cell
90,
405-413[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Langer, R. D.,
Criqui, M. H.,
and Reed, D. M.
(1992)
Circulation
85,
910-915[Abstract/Free Full Text]
|
| 56.
|
Chen, C. H.,
Gray, M. O.,
and Mochly-Rosen, D.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
12784-12789[Abstract/Free Full Text]
|
| 57.
|
Corder, R.,
Douthwaite, J. A.,
Lees, D. M.,
Khan, N. Q.,
Viseu Dos Santos, A. C.,
Wood, E. G.,
and Carrier, M. J.
(2001)
Nature
414,
863-864[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y. Fang and M. E. Olah
Cyclic AMP-Dependent, Protein Kinase A-Independent Activation of Extracellular Signal-Regulated Kinase 1/2 Following Adenosine Receptor Stimulation in Human Umbilical Vein Endothelial Cells: Role of Exchange Protein Activated by cAMP 1 (Epac1)
J. Pharmacol. Exp. Ther.,
September 1, 2007;
322(3):
1189 - 1200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ciccarelli, I. D'Alimonte, P. Ballerini, M. D'Auro, E. Nargi, S. Buccella, P. Di Iorio, V. Bruno, F. Nicoletti, and F. Caciagli
Molecular Signalling Mediating the Protective Effect of A1 Adenosine and mGlu3 Metabotropic Glutamate Receptor Activation against Apoptosis by Oxygen/Glucose Deprivation in Cultured Astrocytes
Mol. Pharmacol.,
May 1, 2007;
71(5):
1369 - 1380.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Das, A. Tosaki, D. Bagchi, N. Maulik, and D. K. Das
Resveratrol-Mediated Activation of cAMP Response Element-Binding Protein through Adenosine A3 Receptor by Akt-Dependent and -Independent Pathways
J. Pharmacol. Exp. Ther.,
August 1, 2005;
314(2):
762 - 769.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. L. Lucas, R. A. Brown, M. Wassef, and T. D. Giles
Alcohol and the Cardiovascular System: Research Challenges and Opportunities
J. Am. Coll. Cardiol.,
June 21, 2005;
45(12):
1916 - 1924.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Das, G. A. Cordis, N. Maulik, and D. K. Das
Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation
Am J Physiol Heart Circ Physiol,
January 1, 2005;
288(1):
H328 - H335.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. F. Liu and Y. H. Wong
G16-mediated Activation of Nuclear Factor {kappa}B by the Adenosine A1 Receptor Involves c-Src, Protein Kinase C, and ERK Signaling
J. Biol. Chem.,
December 17, 2004;
279(51):
53196 - 53204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Batkai, P. Pacher, D. Osei-Hyiaman, S. Radaeva, J. Liu, J. Harvey-White, L. Offertaler, K. Mackie, M. A. Rudd, R. D. Bukoski, et al.
Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension
Circulation,
October 5, 2004;
110(14):
1996 - 2002.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Headrick, B. Hack, and K. J. Ashton
Acute adenosinergic cardioprotection in ischemic-reperfused hearts
Am J Physiol Heart Circ Physiol,
November 1, 2003;
285(5):
H1797 - H1818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Offertaler, F.-M. Mo, S. Batkai, J. Liu, M. Begg, R. K. Razdan, B. R. Martin, R. D. Bukoski, and G. Kunos
Selective Ligands and Cellular Effectors of a G Protein-Coupled Endothelial Cannabinoid Receptor
Mol. Pharmacol.,
March 1, 2003;
63(3):
699 - 705.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|